Tocagen (TOCA) and Osmotica Pharmaceuticals (OSMT) Critical Comparison

Osmotica Pharmaceuticals (NASDAQ:OSMT) and Tocagen (NASDAQ:TOCA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.


This table compares Osmotica Pharmaceuticals and Tocagen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals N/A N/A N/A
Tocagen -222.81% -71.61% -46.13%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Osmotica Pharmaceuticals and Tocagen, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osmotica Pharmaceuticals 0 0 4 0 3.00
Tocagen 0 0 5 0 3.00

Osmotica Pharmaceuticals currently has a consensus price target of $17.50, indicating a potential upside of 123.21%. Tocagen has a consensus price target of $22.80, indicating a potential upside of 76.47%. Given Osmotica Pharmaceuticals’ higher possible upside, equities analysts plainly believe Osmotica Pharmaceuticals is more favorable than Tocagen.

Institutional and Insider Ownership

29.7% of Tocagen shares are held by institutional investors. 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Osmotica Pharmaceuticals and Tocagen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals $245.74 million 1.64 -$45.15 million N/A N/A
Tocagen $40,000.00 6,443.85 -$38.92 million ($2.66) -4.86

Tocagen has lower revenue, but higher earnings than Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Tocagen Company Profile

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply